In a recent video interview with Applied Clinical Trials, Michael Liu, medical student and researcher at Harvard Medical School, discussed a recent study on National Institutes of Health (NIH) grant cuts. Among other notable findings, the study highlighted that 20% of terminated grants were early career training grants, which are crucial for maintaining biomedical research pipelines. Liu also highlighted how the cuts have disproportionately affected institutions nationwide and compromised ongoing clinical trials, particularly those involving marginalized populations.
ACT: What do you think the future holds for the clinical research industry amidst the funding cuts?
Liu: I think it remains to be seen. One essential thing is just continued data monitoring and transparency from the government. I think that’s one of the biggest things that we hope that our study is a call to action for. It’s a really great step that the administration has put out this database of terminator grants, but there’s so much more, making it easily accessible to pick out which ones are clinical trials and what topic areas of these trials they are. I think that’s critically important. As all of you know, the NIH is publicly funded, and as the public, we deserve to have the knowledge. I think beyond that, also understanding what are the reasons behind grand terminations. That is a huge limitation that we don’t understand. It doesn’t give researchers and trialists the opportunity to respond to be able to make adjustments to whatever their projects are. I think that’s an important next step. I think we just need to continue to monitor what’s going on and what the impact will be on the clinical research landscape.